Change in taste · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (systemic clonazepam) changes change in taste compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (alpha lipoic acid +/- vitamins) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · gabapentin with adjunctive ALA
SoF2 subgroup. Gabapentin + adjunctive ALA vs placebo forms one of two subgroups of the anticonvulsant symptom-relief estimate (RR 4.00, 2.09 to 7.67); no between-subgroup difference vs gabapentin alone; 100…
1 study · 40 participants
Very low
Change in taste · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
QoL · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months)
SoF1. Change in QoL short-term (mean Beck Depression Inventory, 0-63, lower better): this single study narratively reported that both intervention and placebo participants were less depressed at trial completion, but…
1 study · 37 participants
Very low
Clinical resolution (oral lesion not completely resolved) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 2, Clinical resolution (not completely resolved) at 5 to 12 months: 'The 3 studies could not be combined in meta-analysis. 2 found benefit for systemic beta carotene, and 1 did not.' No GRADE rating. Effects text…
3 studies
GRADE not reported
Adverse events: worsening of hypertension · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (alpha lipoic acid +/- adjunctive ingredients) changes adverse effects: increase in blood pressure compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx
Non-specific immunotherapy (recombinant interleukin-2 or BCG cell… showed no clear difference in adverse effects compared with standard therapy alone; GRADE not reported.
9 findings from 1 review
RR 11.00 [0.67, 179.29]
1 study · 24 participants
GRADE not reported
RR 3.40 [0.15, 77.34]
1 study · 30 participants
GRADE not reported
RR 1.47 [0.75, 2.90]
1 study · 30 participants
GRADE not reported
Show 6 more findings
RR 0.57 [0.22, 1.50]
1 study · 30 participants
GRADE not reported
RR 0.67 [0.13, 3.30]
1 study · 24 participants
GRADE not reported
RR 0.38 [0.04, 3.26]
1 study · 30 participants
GRADE not reported
RR 1.24 [0.90, 1.70]
1 study · 30 participants
GRADE not reported
RR 1.71 [0.33, 8.83]
1 study · 30 participants
GRADE not reported
RR 5.00 [0.27, 94.34]
1 study · 24 participants
GRADE not reported
Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx
Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… led to higher adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.
9 findings from 1 review
RR 2.02 [1.23, 3.32]
1 study · 67 participants
GRADE not reported
RR 1.04 [0.98, 1.11]
1 study · 226 participants
GRADE not reported
RR 15.53 [2.18, 110.55]
1 study · 67 participants
GRADE not reported
Show 6 more findings
RR 6.57 [3.60, 12.00]
1 study · 191 participants
GRADE not reported
RR 1.22 [0.96, 1.56]
2 studies · 286 participants
GRADE not reported
RR 1.03 [0.94, 1.11]
2 studies · 286 participants
GRADE not reported
RR 1.03 [0.82, 1.28]
2 studies · 286 participants
GRADE not reported
RR 1.11 [0.83, 1.49]
3 studies · 484 participants
GRADE not reported
RR 1.25 [0.54, 2.88]
4 studies · 544 participants
GRADE not reported
Xerostomia (dry mouth relief) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Johnson 1993: positive response (>25 mm change in VAS score) in 25% of participants on placebo, 51% on pilocarpine 5 mg tds, 47% on pilocarpine 10 mg tds. LeVeque 1993: positive response in 7% on placebo vs 42% on…
2 studies · 278 participants
GRADE not reported
Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx
10 findings from 1 review
Mucositis all grades: not estimable due to high heterogeneity (P=0.0009; I2=86%) between subgroups (cetuximab; nimotuzumab) and within cetuximab (I2=93%); 1417 participants, 3 studies. Table 3, row 1.6 (Ang 2014;…
3 studies · 1417 participants
GRADE not reported
RR 6.56 [5.35, 8.03]
2 studies · 1311 participants
GRADE not reported
RR 1.36 [0.80, 2.31]
2 studies · 1311 participants
GRADE not reported
Show 7 more findings
Oral mucositis (severe) · All patients with cancer who are receiving treatment
Oral cryotherapy (ice chips, ice-cold water, ice cubes or crushed… probably leads to lower oral mucositis (severe) compared with control (no treatment or standard/usual oral care, e.g. saline rinse) (moderate certainty).
3 findings from 1 review
RR 0.38 [0.20, 0.72]
5 studies · 270 participants
Moderate
RR 0.88 [0.61, 1.25]
1 study · 122 participants
Very low
RR 0.40 [0.27, 0.61]
5 studies · 444 participants
Moderate
Oral mucositis (severe) · Patients with osteosarcoma (bone cancer) receiving high-dose methotrexate, vincristine and leucovorin
1 finding from 1 review
Oral mucositis (severe). Not estimable - no participants had developed severe oral mucositis by the fourth day after chemotherapy when the data were reported (Zhang 2011, Analysis 4.3, subgroup 3.2); 81 participants in…
1 study · 81 participants
GRADE not reported
Parasympathomimetic drugs (choline esters, cholinesterase inhibitors) vs No treatment
Outcome not reported · Patients with radiation-induced salivary gland dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Number of days of treatment with opioid analgesics · All patients with cancer who are receiving treatment
The review found no eligible studies for this question.
2 findings from 1 review
Disease-free survival · People with squamous cell carcinoma of the oral cavity or oropharynx
It is very uncertain whether non-specific immunotherapy (recombinant interleukin-2 or BCG cell… changes disease-free survival compared with standard therapy alone (very low certainty).
1 finding from 1 review
Progression‐free survival · People with squamous cell carcinoma of the oral cavity or oropharynx
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… showed no clear difference in progression-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.
2 findings from 1 review
Quality of life · All patients with cancer who are receiving treatment
2 findings from 1 review
Summary of findings 2 (melphalan/HSCT): Quality of life - '1 study assessed this outcome but the data are currently unavailable as the study report and analysis have not yet been completed' (Toro 2013; measured with…
1 study
GRADE not reported
Summary of findings for the main comparison (5FU solid cancers): Quality of life - 'No studies assessed this outcome'.
0 studies
No studies found
Adverse events · All patients with cancer who are receiving treatment
2 findings from 1 review
Adverse events reported narratively: one study did not report adverse events (Askarifar 2015); another reported no serious adverse events (Toro 2013); the remaining two reported low rates of shooting pain from the…
3 studies
GRADE not reported
Adverse events reported narratively (not meta-analysed): one study reported no adverse effects (Katranci 2012); the other four 5FU studies reported low rates of very minor adverse events (headache, chills,…
5 studies · 444 participants
GRADE not reported
Oral mucositis (severe) · Patients with osteosarcoma (bone cancer) receiving high-dose methotrexate, vincristine and leucovorin
1 finding from 1 review
Oral mucositis (severe). Not estimable - no participants had developed severe oral mucositis by the fourth day after chemotherapy when the data were reported (Zhang 2011, Analysis 4.3, subgroup 3.1); 118 participants…
1 study · 118 participants
GRADE not reported